THE NORTHERN SWEDEN HEALTH AND DISEASE STUDY COHORT: THE MEDICAL BIOBANK
The Northern Sweden Health and Disease Study Cohort contains three subcohorts: the Västerbotten intervention programme cohort, the MONICA cohort, and the mammary (mammography) screening cohort. The two first cohorts have been used for the cardiovascular and diabetes studies described in this paper.
Originally, the Vä sterbotten Intervention Programme (VIP) is a long-term project intended for health promotion of the population in the county of Vä sterbotten (approx. 254,000 inhabitants). All individuals 40, 50, and 60 years of age in the county's population are invited for screening. They are asked to complete a questionnaire concerning various lifestyle factors including diet and to donate a blood sample for frozen storage for later research purposes. The project started in 1985 and by December 2002 the cohort included 74,000 individuals, of whom 67,000 had donated blood samples. From 1994 a second sample (and questionnaire) has been taken with a 10-year interval of the individuals within the cohort. The material is supplemented with samples from a local mammary screening programme (44,000 sampling occasions, 25,700 unique individuals). From 1997 repeated screening has started within the mammary screening programme with sampling every second year, in the age group 50 -69 years within the county. The Northern Sweden MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) project (screening 1986, 1990, 1994, and 1999 ) contains material from 11,000 sampling occasions and 7,500 unique individuals. The total cohort and the Medical biobank contains at present 85,000 unique individuals with 130,000 sampling occasions. The VIP and MONICA cohorts are population based and the mammary screening cohort are ''nearly'' population based.
Organization of data collection into a Medical Biobank
Questionnaire. Every attending subject is asked to answer a questionnaire, which in the VIP and MONICA projects includes questions about education, occupation/working conditions, daily habits including smoking, diet, etc. and in the mammary screening cohort on reproductive conditions. The dietary questionnaire has been validated twice (1, 2) .
The data from the questionnaires, as well as from results from the biobank, are kept in a database for future research purposes. The questionnaires in the VIP and the MONICA project are optically read. To estimate food habits and food intake a food frequency table containing 84 food items has been used in VIP in 1992 -97 and in MONICA in 1986 MONICA in , 1994 MONICA in , and 1999 . The number of questions was reduced in the MONICA screening 1990 and in the VIP cohort for all other years for priority reasons.
The biobank. The participants are asked for their willingness to donate a sample of 20 ml whole blood for future analyses. The sample is taken after four hours of fasting (20%) or in the morning after overnight fasting (80%) in the VIP and MONICA cohorts. For the participants in mammary screening the time since the last meal is registered. The 20 ml blood sample is divided into 10 subsamples consisting of six plasma, two leucocyte (buffy coat) and two erythrocyte samples, each containing 1.5 ml. All material is placed in freezers at x70 ‡C. The organization of the bank includes specially trained staff and an organization of standardized transport, storage, and security facilities. For DNA handling a specialized laboratory has been established.
Registries. At regular intervals the cohort is scanned for incident myocardial infarctions (MI) and stroke using the Northern Sweden MONICA registry and for cancer using the regional cancer regi-stry. The same procedure has also started for other registries, e.g. diabetes, osteoporosis, Alzheimer's disease.
Coordination with other cohorts. The basic concept of the project is to develop, combine, and use the power of several cohorts. After many years of preparation and recruitment we have now reached the point when the scientific phase has started, a number of projects have been launched and finalized, and the functional structure of the group has been clarified. Several groups of scientists representing different research areas, universities, and countries are participating. Research in functional genomics combined with bioinformatics and biocomputing has high priority at the moment. To obtain sufficient materials various pooling projects (the MORGAM project, the EPIC project, the Joint Nordic Prospective Cohort project, and the Three Country Cohort Study) have high priority.
Availability of samples and the database. The Northern Sweden Health and Disease Study and the Medical Biobank are positioned as a national and international resource for scientific research and scientists from different countries are also applying for samples and information from the database. This process will continue and expand into new areas. The evaluations of individual research projects are done on scientific merits, by specific groups of appointed scientists from the Medical faculty of Umeå University and from some other universities and institutes. The Medical Biobank is organized within the administrative structure of Umeå University Hospital with a board and a director. Ethical considerations. To develop the ethical foundation, we have participated in a large number of public discussions within the scientific community and in the press locally and internationally (3, 4) .
Informed consent was collected from the start of the project, which makes clear to the participants that the material will be used for future research purposes and that all projects will be reviewed and approved by the local research ethics committee. Informed consent for each new purpose is now becoming the main rule for all cardiovascular projects involving use of genetic material and for industrial research.
Quality control and security. The former Swedish Medical Research Council's (MRC) ethics committee has developed and published ethical guidelines on the use and control of ''Biobanks -tissue and health science information banks that can be used for genetic research''. The guidelines propose that the quality of the material stored and the rules for selecting material to be stored should be strictly controlled. Thus a system for Quality Assurance (QA) is suggested.
Since 2001 a system of QA (Good Biobanking Practice) has been used on a routine basis at the Medical Biobank in Umeå ; at regular intervals quality control and audit are performed.
Quality Assurance (QA) is a continuous process that aims at measuring, evaluating and continuously re-evaluating the quality and when required, changing and improving the quality. In order to do so:
. The quality assurance work should have an aim (plan of activity and schedule for work). . All the employees of a biobank should be involved in the QA system. . Results should be followed up, reported, and analysed. . Corrective measures should be carried out based on the analyses. . Auditing by an external expert/organization should be done regularly.
The QA system must guarantee that the products (biological samples, questionnaires, and data) that are managed have the quality that corresponds to the intended use. The QA will cover all activities in a biobank such as purchasing of material, selecting contractors, licensing the staff to perform different assignments, sample collection, sample transport, sample storage, sample retrieval and all handling of measurements and data until ''the product'' is delivered. It is important to guarantee the quality of the individual sample/piece of information and to ensure that all activities (including mistakes) of every sample/ information can be tracked down and documented.
EXAMPLES OF APPLICATION OF THE MEDICAL BIOBANK TO SPECIFIC STUDIES
Studies in stroke: the CASTRO studies Stroke is a major cause of disability and death in all developed countries and a rapidly increasing health threat even in most developing countries. According to the WHO MONICA project the lowest average annual attack rate for stroke among participating countries was found in Friuli, Italy, and the highest in Novosibirsk, Russian Federation (5) . The aim of the present studies on stroke is to explore the role of different factors as predictors of first-ever stroke in people of comparatively young ages. We have used an incidence case-reference design, as the incident study design makes it possible to collect survey data prior to the onset of stroke and then to make the comparisons between cases and referents as incident events occur.
A series of studies have been performed as incident case-control studies nested in the VIP and MONICA cohorts on 129 stroke cases and 258 controls (Figure 1) .
A second study is ongoing with approximately 350 prospective cases from the same cohort. A corresponding number of retrospective cases are also available, which makes the number of cases large enough for a variety of genetic studies.
Results of the CASTRO studies predicting stroke by traditional risk factors History of diabetes, daily smoking, obesity (body mass index¢30), hypertension, and single marital status were associated with an increased risk of stroke (6) . Interaction of possible clinical relevance was observed between hypertension, history of diabetes, and stroke. The results of the study emphasized the importance of a multifactorial approach when preventing stroke in clinical work.
Inflammation and infections related to stroke. There are continuous discussions in the literature on the relationship between infections, inflammation, various immunological mechanisms, and their relation to cardiovascular disease. Some results of studies of the cohort are given below:
. Anticardiolipin antibodies have been proposed to be an independent risk factor for stroke. IgM-aCL were present in 11.3% (14/123) of the stroke patients and in 3.7% (9/241) of the healthy controls (7) . . No association was found with autoantibodies against oxidatively modified LDL and stroke. Their possible pathogenic role is still unclear. Perhaps they only represent an innocent bystander with no direct correlation to the atherosclerotic process (8) . . Chlamydia pneumoniae antibodies did not predict ischaemic stroke. Follow-up studies are planned on other markers of distant infections (9) .
Fibrinolysis, leptin, proinsulin, and stroke. An association of various forms of metabolic aberrations such as insulin resistance, obesity, impaired glucose tolerance, dysfibrinolysis, and cardiovascular disease is well known. A number of observations have been made which support this concept:
. The tPA-PAI-1 complex is a novel fibrinolytic marker for stroke. The complex was independently associated with first-ever stroke, especially haemorrhagic strokes. The findings support the hypothesis that disturbances in fibrinolysis precede a cerebrovascular event (10) .
. Plasma leptin was strongly associated with an increased risk for first-ever haemorrhagic stroke (OR21) independent of other risk markers of CVD. The number of cases was limited, hence a large confidence interval (11) . High proinsulin levels preceded first-ever stroke in a non-diabetic population. Proinsulin may act as a marker for a metabolic disturbance like leptin. All individuals with known or unknown diabetes were excluded. The OR for women was surprisingly high at 14 (12) .
Studies in acute myocardial infarction (AMI): the FIA studies
The very high mortality of AMI was the starting point of the VIP project in 1985 with the combined purpose of decreasing the incidence of AMI and identifying new risk markers/factors of AMI. A series of studies have been performed as nested case-control studies using the VIP and MONICA cohorts on 78 cases and 156 controls. A second series of studies are now planned with approximately 500 incident cases from the same cohort. The results of some published studies are given below. Traditional risk factors and AMI. Smoking, hypercholesterolaemia, history of diabetes, and hypertension had an important impact on the incidence of AMI, and perceived ill health increased the negative effect of these risk factors (13) . It was also found that lipoprotein(a) acted synergistically with total plasma cholesterol and that apolipoprotein A1was protective of acute AMI (14) .
Fibrinolysis, leptin, proinsulin, homocystein and AMI. Metabolic factors have long been associated with an increased risk of AMI:
. Plasma concentrations of plasmin activator inhibitor (PAI-1), tissue-type plasmin activator (tPA) and von Willebrand factor (vWF) were all associated with development of a first AMI. For tPA this association was independent of established risk factors (OR 5.4) (15). . Plasma leptin strongly predicted first-ever MI. A high leptin concentration remained as an independent risk factor in a multivariate model (OR 9.0) (16). . A high proinsulin concentration preceded acute AMI in non-diabetics (OR 3.5). The impact of proinsulin was independent of traditional risk factors of AMI (17) . . Total plasma homocysteine was not associated with an increased risk of AMI and no interactions were seen between the three different genotypes of MTHFR and plasma (18) homocystein concentrations.
CONCLUDING STATEMENTS CONCERNING STROKE, AMI, AND INFLAMMATION
It is important to identify new risk factors and to evaluate the significance of traditional risk factors. This knowledge will provide a basis for future preventive actions with the purpose of changing the trend in the right direction also for stroke in Northern Sweden, as has occurred for AMI. There was a striking similarity in the risk factor pattern of the two major forms of CVD: stroke and AMI. It is important, but by no means enough, to focus on blood pressure and blood cholesterol control. Diabetes control, smoking cessation, and reduction in weight must also be considered as factors of major importance for prevention of cardiovascular disease. In the future we may also focus on other risk indicators/factors such as leptin, proinsulin, and the tPA-PAI-1 complex, identified in the studies of the cohort.
Inflamed vessel walls may be the common denominator for both AMI and stroke Atherosclerosis may be considered as an inflammatory disease (19) . A longstanding inflammatory process results in an accumulation of macrophages and lymphocytes in the atherosclerotic lesions. A decrease in strength of the vessel wall by various factors involved in the inflammatory process, such as activation of inflammatory cells, cytokines and proteolytic enzymes, might be of crucial importance in the pathogenesis of both stroke and AMI. Cytokines are modulators of inflammation and immune responses and the balance between pro-inflammatory and anti-inflammatory stimuli may be crucial for a rupture of the vessel wall or an atherosclerotic plaque. The following observations from studies performed so far on the cohort support the concept that various aspects of inflammatory conditions/processes in the vessel wall are crucial for events of stroke as well as acute AMI:
. The association with increased leptin concentration and insulin resistance/increased proinsulin concentration (11, 12, 16, 17) : There is evidence for close similarities in structure and functions between cytokines and leptin as well as an association of both with the insulin resistance syndrome. High concentrations are often found of cytokines and leptin in insulin-resistant individuals. There is also experimental evidence from several studies for direct interactions between cytokines (e.g. TNF-a and IL-1) and leptin. The interaction is usually demonstrated as an increased excretion of leptin induced by cytokines but also vice versa, as in macrophages where leptin may stimulate both cytokine production and phagocytosis. Leptin may also exert other proinflammatory effects like maturation of lymphocytes into more proinflammatory phenotypes, characterized by production of proinflammatory cytokines such as interferon-c and IL-2. . The association of high tPA and PAI-1 concentrations (10, 15) : The finding that disturbances in fibrinolysis precede stroke as well as AMI may also reflect inflammatory events in the vessel wall. PAI-1 is related to insulin resistance, which by itself may influence inflammation as indicated above. The association with tPA mass concentration may be explained by its relationship with a combination of different mechanisms, including insulin resistance, inflammatory conditions of the vessel wall, and endothelial dysfunction or endothelial cell damage. The most convincing evidence related to endothelial dysfunction or damage is associated with an activation of macrophages located in the vessel wall with a continued release of cytokines and proteolytic vessel wall degrading enzymes. . The association with cardiolipin antibodies with stroke (7) gives further evidence for an inflammatory component in stroke.
Thus, we believe that support is given by our results of atherosclerosis as an inflammatory disease. The challenge is to inhibit harmful components of the inflammatory process and to promote healing of the vessel wall and consequently prevent complications like stroke and AMI. While the inflammatory process is multifactorial, several routes for diagnosis, treatment, and prevention can be tried. For early diagnosis of ongoing processes preceding events of AMI and stroke, a combination of biomarkers used in the present studies may possibly in the future be useful for predicting clinical events. Studies on repeat sampling and measurements of biomarkers in the cohorts will give us better information and perspectives to formulate preventive strategies for AMI and stroke in the future. One route for prevention of AMI and stroke is diet. A protective effect on AMI has been associated with fish intake and long-chain omega-3 fatty acids in the cohort (20) , which may be related to inhibitory effects on activated macrophages.
Studies in diabetes
The population-based material of oral glucose tolerance tests (OGTT) performed within the VIP and MONICA cohorts is unique in numbers combined with length of follow up. In a first cross-sectional study on 22,000 men and women in the VIP cohort, subjects with impaired glucose tolerance (IGT), along with the diabetic subjects, had higher BMI, plasma triglycerides, and blood pressure than individuals with a normal test. A higher proportion of subjects with low physical activity and a high BMI were seen in the group of unknown IGT and undiagnosed diabetes compared with normal individuals and previously diagnosed diabetics (21) .
In a second study individuals at risk for type 1 diabetes in the VIP cohort were screened for GAD antibodies, GAD 65 Ab. Impaired OGTT was correlated with GAD65 Ab. Independent of the OGTT results an unexpected association was found between high levels of GAD65Ab and a high BMI (22) .
A third follow-up study has just been performed as a pilot study where the medical records of 2,183 subjects in the VIP study were reviewed for the diagnosis of diabetes. One conclusion from this procedure is that active follow up is needed for correct diagnosis of diabetes.
Islet cell autoantibodies (GAD65Ab and IA-2Ab) did not predict diabetes (40 new cases) at follow up. BMI measured at baseline was as effective as twohour plasma glucose at OGTT and fasting plasma glucose to predict diabetes in this adult population (23) .
CONCLUDING REMARKS
Since 1985 a cohort of 85,000 unique individuals has been established. A new system for quality control in biobanks called ''Good Biobanking Practice'' has been developed. The intention is to invite other biobanks to use the same system with the purpose of facilitating cooperative pooling studies between biobanks. The Northern Sweden Health and Disease Study is positioned as a national and international resource for scientific research. Scientists from the whole of Sweden but also from other countries are applying for samples and information from the database. This process will continue and it now covers several disease areas: Cardiovascular disease, Diabetes, Cancer, Multiple Sclerosis, Alzheimer's disease, Osteoporosis. The evaluation of the projects is done on scientific merits by specific groups of appointed scientists from the medical faculty of Umeå University and from some other universities and institutes. Most studies are performed using the nested case-control design, which usually gives cost-effective results with a high scientific value/quality.
